Terms: = Ovarian cancer AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1 AND Treatment
9 results:
1. pik3r1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
2. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
[TBL] [Abstract] [Full Text] [Related]
3. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via pik3r1 upregulation.
Li H; Lin R; Zhang Y; Zhu Y; Huang S; Lan J; Lu N; Xie C; He S; Zhang W
Mol Cancer; 2024 Jan; 23(1):5. PubMed ID: 38184597
[TBL] [Abstract] [Full Text] [Related]
4. Low expression of m6A reader YTHDC1 promotes progression of ovarian cancer via pik3r1/STAT3/GANAB axis.
Wang X; Chen Q; Bing Z; Zhou S; Xu Z; Hou Y; Zhao Y; Zhao S; Wang T
Int J Biol Sci; 2023; 19(14):4672-4688. PubMed ID: 37781028
[No Abstract] [Full Text] [Related]
5. Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery.
Hossain MA; Sohel M; Rahman MH; Hasan MI; Khan MS; Amin MA; Islam MZ; Peng S
PLoS One; 2023; 18(1):e0265746. PubMed ID: 36608061
[TBL] [Abstract] [Full Text] [Related]
6. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract] [Full Text] [Related]
7. Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H; Saleem A; Babar S; Dina R; El-Bahrawy MA; Curry E; Rama N; Chen M; Pickford E; Agarwal R; Blagden S; Carme S; Salinas C; Madison S; Krachey E; Santiago-Walker A; Smith DA; Morris SR; Stronach EA; Gabra H
J Nucl Med; 2015 Dec; 56(12):1828-35. PubMed ID: 26429956
[TBL] [Abstract] [Full Text] [Related]
8. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
Han G; Soslow RA; Wethington S; Levine DA; Bogomolniy F; Clement PB; Köbel M; Gilks B; DeLair D
Int J Gynecol Pathol; 2015 Jul; 34(4):323-33. PubMed ID: 25851704
[TBL] [Abstract] [Full Text] [Related]
9. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
[TBL] [Abstract] [Full Text] [Related]
